抗真菌管道:用于治疗真菌病的新工具
Stella Wolfgruber1, Jon Salmanton-García2, Marius Paulin Ngouanom Kuate3
1Division of Infectious Diseases, Medical University of Graz, Graz, Austria; Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.
Revista iberoamericana de micologia
|March 1, 2025
概括
新的抗真菌药物提供了新的机制和降低毒性,以对抗日益增长的真菌感染和耐药性. 挑战仍然存在,特别是在低收入和中等收入国家,需要进一步的研究和开发.
科学领域:
- 医学真菌学 医学真菌学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 真菌感染对公众健康构成重大威胁,特别是对免疫力低下的人群.
- 目前的抗真菌治疗显示出有限的疗效,不良反应,并增加药物耐药性.
- 由于宿主-病原体相似性和新兴的耐药性模式,现有的抗真菌类面临挑战.
研究的目的:
- 审查新型抗真菌剂及其作用机制.
- 探索抗真菌药物在低收入和中等收入国家 (LMIC) 的挑战和治疗作用.
- 突出全球对抗真菌耐药性的关注以及需要新的干预措施.
主要方法:
- 关于新抗真菌剂的综合文献审查.
- 对新型抗真菌药物的作用机制的分析.
- 检查LMICs在真菌感染和治疗获取方面的挑战.
主要成果:
- 像ibrexafungerp,rezafungin,oteseconazole和miltefosine这样的新药显示出新的机制和改进的安全性.
- 抗真菌耐药性是一个日益严重的全球性问题,低低收入国家面临着机会性和特有真菌病的高负担.
- 对抗真菌药物的有限获取和滥用加剧了LMICs的挑战.
结论:
- 新型抗真菌剂为对抗耐药真菌感染提供了有希望的替代品.
- 解决LMIC中不成比例的真菌病负担需要改善对诊断和治疗的准入.
- 持续的研究和开发对于管理不断升级的真菌感染全球威胁至关重要.
关键词:
ATI2307 在线电话福斯曼诺格皮克斯 (Fosmanogepix) 是一个古老的生物.GR239797 格兰地2397 格兰地2397 格兰地在Ibrexafungerpp中使用这是一个LMIC.低收入和中等收入国家.MAT2203 的时间.米尔特福西纳 (Miltefosina) 是一种葡萄糖.米尔特福西尼 (Miltefosine) 是一种在NP339中,我们得到了NP339.新型抗真菌药物 新型抗真菌药物新的抗真菌药物 抗真菌药物油脂的使用方法这种药物是Opelconazol.这种药物是Opelconazole.PRMB PRMB 是一个很大的问题.中等和低收入收入国家.在Rezafungin中使用.在Rezafungina中使用.
相关概念视频
01:28Fungal Phylum Microsporidia
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...